抗氧化应激治疗和当前的临床试验
1Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States.
World journal of hepatology
|March 18, 2024
概括
氧化应激,反应性氧物种 (ROS) 的失衡,是慢性疾病的关键. 虽然抗氧化应激剂在临床前表现有希望,但需要更多的临床试验来确认它们在治疗疾病中的有效性.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生物化学
- 病理生理学 病理生理学
背景情况:
- 氧化应激破坏了反应性氧物种 (ROS) 生产和排毒之间的平衡.
- 这种不平衡与许多慢性疾病的发展和进展有关.
- 细胞对氧化应激的反应涉及各种信号通路,包括应激适应,炎症,缺氧反应,DNA修复和抗氧化反应.
研究的目的:
- 审查当前研究抗氧化应激治疗各种疾病的临床试验.
- 突出抗氧化应激剂的临床前承诺和临床验证之间的差距.
- 强调需要在这个治疗领域进行进一步的研究.
主要方法:
- 对抗氧化应激治疗的当前临床试验的文献综述.
- 讨论氧化应激和相关信号通路在疾病中的作用.
- 对抗氧化应激剂从临床前到临床环境的转化进展的分析.
主要成果:
- 氧化应激是多种疾病病理的一个重要因素.
- 氧化应激激活了各种信号通路,提供了治疗点.
- 尽管进行了广泛的临床前研究,但有限的临床试验已经评估了抗氧化应激剂的有效性.
结论:
- 氧化应激代表了一系列疾病的有前途的治疗标.
- 进一步的临床前和临床研究对于验证抗氧化应激策略至关重要.
- 抗氧化应激剂可以作为疾病治疗或食补充剂,以提高治疗结果.
相关概念视频
01:46Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K
01:22Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186